论文部分内容阅读
目的探讨卡铂联合紫杉醇对老年晚期卵巢癌患者的临床疗效及血清人附睾分泌蛋白4(HE4)、糖类抗原125(CA125)水平的影响。方法选择2013年2月到2015年2月收治的64例老年晚期卵巢癌患者,随机分为试验组和对照组,各32例。对照组患者给予顺铂联合紫杉醇化疗,试验组患者给予卡铂联合紫杉醇化疗,均治疗2个疗程。评价并比较两组患者临床疗效与治疗期间不良反应发生情况,观察两组患者治疗前后血清HE4和CA125水平及肿瘤转移率。结果试验组患者的有效率和疾病控制率分别为78.13%和96.88%,明显高于对照组(53.13%和75.00%),差异具有统计学意义(P<0.05)。治疗后,两组患者血清HE4、CA125水平均显著降低(P<0.05),其中试验组患者血清HE4、CA125水平明显低于对照组,差异具有统计学意义(P<0.05)。试验组患者的不良反应发生率为21.88%,明显低于对照组患者的56.25%,差异具有统计学意义(P<0.01)。治疗后,试验组患者的肿瘤转移率为15.63%,明显低于对照组的40.63%,差异具有统计学意义(P<0.05)。结论卡铂联合紫杉醇治疗老年晚期卵巢癌的临床疗效显著,能明显降低患者肿瘤转移率及血清HE4和CA125水平,不良反应发生率低,值得临床上推广应用。
Objective To investigate the clinical efficacy of carboplatin combined with paclitaxel in elderly patients with advanced ovarian cancer and the effects of serum epididymal secretory 4 (HE4), carbohydrate antigen 125 (CA125) levels. Methods Sixty-four elderly patients with advanced ovarian cancer who were admitted from February 2013 to February 2015 were randomly divided into experimental group and control group, with 32 cases in each group. Patients in the control group were treated with cisplatin combined with paclitaxel. Patients in the test group were treated with carboplatin combined with paclitaxel and were given 2 courses of treatment. Evaluate and compare the clinical curative effect of the two groups and the occurrence of adverse reactions during the treatment, and observe the serum levels of HE4 and CA125 and tumor metastasis before and after treatment in both groups. Results The effective rate and disease control rate in the experimental group were 78.13% and 96.88%, respectively, which were significantly higher than those in the control group (53.13% and 75.00%). The difference was statistically significant (P <0.05). After treatment, the levels of serum HE4 and CA125 were significantly decreased in both groups (P <0.05). The levels of serum HE4 and CA125 in the test group were significantly lower than those in the control group (P <0.05). The incidence of adverse reactions in the test group was 21.88%, which was significantly lower than that in the control group (56.25%), the difference was statistically significant (P <0.01). After treatment, the tumor metastasis rate in the experimental group was 15.63%, which was significantly lower than that in the control group (40.63%), the difference was statistically significant (P <0.05). Conclusions The efficacy of carboplatin combined with paclitaxel in the treatment of elderly patients with advanced ovarian cancer is significant. It can significantly reduce the tumor metastasis rate and serum HE4 and CA125 levels, and the incidence of adverse reactions is low, which is worth popularizing in clinic.